Τίτλος:
Serum levels of transforming growth factor-β1 in patients with mild psoriasis vulgaris and effect of treatment with biological drugs
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background. Psoriasis is an immune cell-mediated disease in which cytokines play an important role. Studies have been performed to explore the relationship between the disease and cytokine blood levels with a view to finding a biomarker for monitoring disease severity/activity and treatment efficacy. Aim. To investigate the levels of transforming growth factor-β1 (TGF-β1) in patients with mild psoriasis vulgaris (PV) and the possible use of this cytokine in monitoring treatment with biological drugs. Methods. Serum levels of TGF-β1 were estimated in 33 untreated patients (PI group), in 7 of these patients (PII group) before and after 3 months of treatment with one of two biological drugs (etanercept and efalizumab) and in 19 healthy volunteers (control group). Results. Significantly (P < 0.0001) higher serum levels of TGF-β1 were found in the PI group [Psoriasis Area and Severity Index (PASI) 9-10] compared with the 19 healthy volunteers. In the PII group, after the administration of one of the biological drugs, a 50% reduction in PASI and a significant (P = 0.032) decrease in TGF-β1 was noted. Conclusions. Raised TGF-β1 levels in patients with mild PV decreased in tandem with a decrease in PASI after biological drug treatment. Hence, TGF-β1 levels seem to be sensitive to changes in disease severity. © 2008 British Association of Dermatologists.
Συγγραφείς:
Kallimanis, P.G.
Xenos, K.
Markantonis, S.L.
Stavropoulos, P.
Margaroni, G.
Katsambas, A.
Avgerinou, G.
Περιοδικό:
CLINICAL AND EXPERIMENTAL DERMATOLOGY
Λέξεις-κλειδιά:
biological marker; efalizumab; etanercept; transforming growth factor beta1, absence of side effects; adult; aged; article; clinical article; clinical trial; controlled clinical trial; controlled study; disease severity; down regulation; drug monitoring; female; human; male; priority journal; protein blood level; psoriasis vulgaris; scoring system; treatment duration; treatment outcome; treatment response, Adult; Aged; Antibodies, Monoclonal; Biological Markers; Female; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Transforming Growth Factor beta1; Treatment Outcome; Young Adult
DOI:
10.1111/j.1365-2230.2008.03026.x
